

Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!
Mar 28, 2025
Selina Luger, an expert in leukemias, and Curtis Lachowiez, a hematological malignancies authority, discuss groundbreaking strategies for optimizing induction therapy in acute myeloid leukemia. They delve into the exciting results of combining venetoclax with traditional chemotherapy, showcasing enhanced remission rates. Additionally, Luger shares insights from trials comparing FLT3 inhibitors, while Lachowiez highlights the potential of menin inhibitors like Ziftomenib. The conversation also touches on the effectiveness of CPX-351 and future advancement directions in AML treatment.
AI Snips
Chapters
Transcript
Episode notes
Venetoclax Plus CLIA Efficacy
- Combining venetoclax with CLIA chemotherapy yields a 94% composite remission rate in newly diagnosed AML patients under 65.
- This combo achieves deep MRD-negative remissions and supports high rates of allogeneic stem cell transplantation.
Venetoclax Enhances Intensive Regimens
- Adding venetoclax to intensive purine analog-based regimens improves complete remission rates to 90-95% across AML risk groups.
- In relapsed AML, patients without prior venetoclax exposure and TP53 mutations fare best with this therapy.
Venetoclax plus 7+3 Safety and Efficacy
- Venetoclax combined with standard 7+3 induction chemotherapy shows high composite CR rates (85%) and 86% MRD negativity.
- Adding venetoclax does not increase toxicity beyond standard 7+3, and one induction suffices for remission.